[ 1 ]    Jalava J, Vaara M, Huovinen P. Mutation at the position 2058 of the

          2 3 SrRNAas a cause of macrolide resistance in Streptococcuspyogenes

           [J].Ann Clin Microbiol Antimicrob, 2004, 3（1）: 5.

[ 2 ]  Weiss K,Guilbault C, Crotes L,et al. Genotypic characterization of

         macrolide-resistant strains of Streptococcus pneumoniaeisolated in

         Quebec, Canada,andin vitroactivity of ABT-773 and telithromycin

           [J].J Antimicrob Chemother, 2002, 50（ 3 ） :  403-406.

[ 3 ]   NORRBY SR, QUINN J, RANGARAJUM,et al.Evaluation of 5-day

          therapy with telithromycin, a novel ketolide antibacteria, forthe

           treatment of tonsillopharyngitis[J]. Clin Microbiol Infect,2004, 10(7):

           615-623.

[4] Novotny GW, Jakobsen L, Andersen NM,et al. Ketolide

          antimicro-bial activity persists after disruption of interactionswith

           domain of 2 3 SrRNA[J].Antimicrob Agents Chemother, 2004, 48

           (10):3 677-3 683.

[5]    Hand WL,Hand DL,King-Thompson NL. Antibiotic inhibition of the

          respiratory burst response in human polymorphonuclear leuko-cytes[J].

           Antimicrob Agents Chemother,1990,34:8 631.

[6]    Ma Z, Clak RF, Brazzale A,et al. Novel erythromycin derivatives with

          aryl group stethered to the C-6 position are potent protein synthe-sis

          nhibitors and active against multidrug-resistant respiratory pathogens

           [J].J Med Chem, 2001, 44(24):4 137-4 156. 

[7]      Tai-t Kamradt A, DaviesT, Appelbaum PC,et al. Two newmecha-nisms

          of macrolide resistance in clinical strainsofStreptococcuspneu

          -moniaefrom Eastern Europe and North America [J]. Antimicrob

          Agents Chemother, 2000, 44(12):3 395-3 401.